Date: 2015-09-02
Type of information: Nomination
Compound:
Company: Summit Therapeutics (UK)
Therapeutic area: Infectious diseases - Neuromuscular diseases - Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 2, 2015, Summit Therapeutics, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announced the appointment of Dr Ralf Rosskamp as Chief Medical Officer. Dr Rosskamp was most recently Vice President, Global Clinical Development, at NPS Pharmaceuticals, where he oversaw the development of several rare disease drug candidates from early clinical stage through to regulatory approval. Dr Rosskamp will be based in the Company\'s US office in Cambridge, Massachusetts. Dr Rosskamp brings to Summit broad drug development and regulatory expertise from his career in the biotechnology industry. He has been responsible for numerous investigational new drug applications, the design and execution of clinical development programs, and new drug applications across multiple therapeutic areas including rare diseases. Dr Rosskamp has been involved in the approval of a number of products including Amaryl®, Lantus®, Apidra®, Simcor®, and most recently the FDA authorisation of Natpara® for the treatment of a rare endocrine disease called hypoparathyroidism. Prior to joining NPS Pharmaceuticals, which was subsequently acquired by Shire Pharmaceuticals, he was Executive Vice President, R&D at rare disease specialist Ikaria. Dr Rosskamp has also served as Executive Vice President, R&D of Kos Pharmaceuticals (acquired by Abbott Labs), Vice President, Global Therapeutic Area Endocrinology, Metabolism, Rheumatology and Bone at Aventis Pharmaceuticals and Head, Clinical Research - Metabolism and Global Clinical Director, Recombinant Products at Hoechst AG. In his academic career, Dr Rosskamp served as Associate Professor, Pediatric Endocrinology in the Department of Pediatrics at the University of Bonn. He received his MD in paediatrics from the University of Bonn.
Financial terms:
Latest news:
